{"nctId":"NCT00396292","briefTitle":"Comparison of the Safety and Efficacy of Intravenous Iron Versus Oral Iron in Subjects Who Display Postpartum Anemia","startDateStruct":{"date":"2005-02"},"conditions":["Anemia"],"count":361,"armGroups":[{"label":"VIT-45","type":"EXPERIMENTAL","interventionNames":["Drug: VIT-45"]},{"label":"Oral iron tablets","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Oral iron tablets"]}],"interventions":[{"name":"Oral iron tablets","otherNames":["Ferrous Sulfate"]},{"name":"VIT-45","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Female Subjects able to give consent\n* Post partum patients\n* Baseline Hbg\\< /= 10\n* Agree to practice birth control\n* Demonstrate willingness to comply with protocol restrictions\n\nExclusion Criteria:\n\n* Known hypersensitivity reaction to oral or IV iron (VIT-45)\n* Documented history of discontinuing oral iron\n* Significant bleeding\n* History of anemia other that iron deficiency anemia\n* Severe Psychiatric disorders\n* Active severe infection\n* Known Hepatitis B antigen or Hep C viral antibody or active hepatitis\n* Known HIV antibody\n* Received investigational product within 30 days\n* Alcohol abuse\n* Hemochromatosis or other iron storage disorder","healthyVolunteers":false,"sex":"FEMALE","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Subjects Who Achieved 'Success' Meaning a â‰¥ 2.0 Increase in Hemoglobin","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"162","spread":null},{"groupId":"OG001","value":"159","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":174},"commonTop":["Headache","Constipation","Nausea"]}}}